易瑞沙治疗化疗失败的晚期非小细胞肺癌  

Iressa in the Treatment of Advanced Non-Small Cell Lung Cancer Failed to Prioy Chemotherapy

作　　者：王巍[1] 邓燕明[1] 胡斌[1] 庞丹梅[1] 

机构地区：[1]广东省佛山市第一人民医院肿瘤医院内科,520841

出　　处：《实用癌症杂志》2007年第6期614-616,共3页The Practical Journal of Cancer

摘　　要：目的观察易瑞沙治疗化疗失败晚期非小细胞肺癌的疗效和不良反应。方法易瑞沙每天口服250mg治疗化疗失败的30例晚期非小细胞肺癌,1个月以后进行疗效评价,无进展者继续服用,之后每个月行CT检查评价疗效并临床密切观察,病情进展或不能耐受相关毒性者则停止使用易瑞沙。结果30例均可评价疗效,无CR者,PR6例(20.0%),SD14例(46.7%),PD10例(33.3%)。有效率(CR+PR)为20.0%,疾病控制率(CR+PR+SD)66.7%,全组中位无进展生存期为3.0个月(0.7～29.0个月),中位生存期6.4个月(1.7～39.0个月)。主要不良反应包括皮疹22例,腹泻2例。没有患者因毒性不能耐受而停药。结论易瑞沙对化疗失败的晚期非小细胞肺癌具有一定疗效,不良反应轻微。Objective To summarize the efficacy and toxicity of Iressa for refractory patients with advanced non-small cell lung cancer （ NSCLC ） failed to prior chemotherapy. Methods Thirty cases with chemo-refractory NSCLC were enrolled. Iressa 250 mg was administered orally once a day until disease progression or intolerable toxicities. Tumor response and treatment toxicities were assessed by Intensive clinic observation and monthly CT scan. Results All 30 patients were evaluable. There was no complete response （CR）. Partial response （PR） was noted in 6 patients （20.0%）. There were 14 patients （46.7%） with stable disease （SD） and 10 patients （33.0%） with progressive disease （PD）. Disease control rate including complete and partial response and stable disease （ CR ＋ PR ＋ SD） was 66.7%. The median progress free survival and overall survival were 3.0 （0.7 - 29.0） months and 6.4 （ 1.7 - 39.0 ） months, respectively. The main toxicities included skin rash in 22 cases and diarrhea in 2 cases. No patient was withdrawn from the treatment due to intolerable toxicities. Conclusion Iressa is effective and tolerable in the treatment of patients with advanced NSCLC failed to prior chemotherapy.

关 键 词：非小细胞肺癌 易瑞沙 化疗耐药 

分 类 号：R734.2[医药卫生—肿瘤]